ESSA Pharma Competitors

Legend Biotech (NASDAQ:LEGN) and ESSA Pharma (NASDAQ:EPIX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, valuation and risk.

Earnings & Valuation

This table compares Legend Biotech and ESSA Pharma's gross revenue, earnings per share (EPS) and valuation.

ESSA Pharma has lower revenue, but higher earnings than Legend Biotech.

Analyst Recommendations

This is a summary of recent recommendations for Legend Biotech and ESSA Pharma, as provided by MarketBeat.

Legend Biotech currently has a consensus price target of $50.6667, suggesting a potential upside of 115.69%. ESSA Pharma has a consensus price target of $28.80, suggesting a potential upside of 6.82%. Given Legend Biotech's higher probable upside, analysts clearly believe Legend Biotech is more favorable than ESSA Pharma.

Profitability

This table compares Legend Biotech and ESSA Pharma's net margins, return on equity and return on assets.

Insider & Institutional Ownership

18.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 63.4% of ESSA Pharma shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

ESSA Pharma beats Legend Biotech on 5 of the 8 factors compared between the two stocks.

ESSA Pharma (NASDAQ:EPIX) and Karuna Therapeutics (NASDAQ:KRTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares ESSA Pharma and Karuna Therapeutics' revenue, earnings per share and valuation.

Karuna Therapeutics is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

ESSA Pharma has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, Karuna Therapeutics has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for ESSA Pharma and Karuna Therapeutics, as reported by MarketBeat.

ESSA Pharma currently has a consensus target price of $28.80, suggesting a potential upside of 6.82%. Karuna Therapeutics has a consensus target price of $141.70, suggesting a potential upside of 20.22%. Given Karuna Therapeutics' higher possible upside, analysts clearly believe Karuna Therapeutics is more favorable than ESSA Pharma.

Profitability

This table compares ESSA Pharma and Karuna Therapeutics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

63.4% of ESSA Pharma shares are owned by institutional investors. Comparatively, 74.8% of Karuna Therapeutics shares are owned by institutional investors. 18.1% of Karuna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Karuna Therapeutics beats ESSA Pharma on 7 of the 10 factors compared between the two stocks.

ESSA Pharma (NASDAQ:EPIX) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Volatility & Risk

ESSA Pharma has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.

Insider & Institutional Ownership

63.4% of ESSA Pharma shares are owned by institutional investors. Comparatively, 3.1% of MorphoSys shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ESSA Pharma and MorphoSys' revenue, earnings per share and valuation.

ESSA Pharma has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for ESSA Pharma and MorphoSys, as reported by MarketBeat.

ESSA Pharma currently has a consensus target price of $28.80, suggesting a potential upside of 6.82%. Given ESSA Pharma's stronger consensus rating and higher possible upside, research analysts clearly believe ESSA Pharma is more favorable than MorphoSys.

Profitability

This table compares ESSA Pharma and MorphoSys' net margins, return on equity and return on assets.

ESSA Pharma (NASDAQ:EPIX) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.

Risk and Volatility

ESSA Pharma has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500.

Insider and Institutional Ownership

63.4% of ESSA Pharma shares are owned by institutional investors. Comparatively, 92.9% of Agios Pharmaceuticals shares are owned by institutional investors. 3.2% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares ESSA Pharma and Agios Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

ESSA Pharma has higher earnings, but lower revenue than Agios Pharmaceuticals. ESSA Pharma is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for ESSA Pharma and Agios Pharmaceuticals, as reported by MarketBeat.

ESSA Pharma presently has a consensus price target of $28.80, suggesting a potential upside of 6.82%. Agios Pharmaceuticals has a consensus price target of $64.6364, suggesting a potential upside of 37.12%. Given Agios Pharmaceuticals' higher possible upside, analysts plainly believe Agios Pharmaceuticals is more favorable than ESSA Pharma.

Profitability

This table compares ESSA Pharma and Agios Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Agios Pharmaceuticals beats ESSA Pharma on 7 of the 13 factors compared between the two stocks.

ESSA Pharma (NASDAQ:EPIX) and FibroGen (NASDAQ:FGEN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.

Risk and Volatility

ESSA Pharma has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.

Insider and Institutional Ownership

63.4% of ESSA Pharma shares are owned by institutional investors. Comparatively, 75.1% of FibroGen shares are owned by institutional investors. 3.4% of FibroGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares ESSA Pharma and FibroGen's revenue, earnings per share (EPS) and valuation.

ESSA Pharma has higher earnings, but lower revenue than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for ESSA Pharma and FibroGen, as reported by MarketBeat.

ESSA Pharma presently has a consensus price target of $28.80, suggesting a potential upside of 6.82%. FibroGen has a consensus price target of $53.5714, suggesting a potential upside of 58.73%. Given FibroGen's higher possible upside, analysts plainly believe FibroGen is more favorable than ESSA Pharma.

Profitability

This table compares ESSA Pharma and FibroGen's net margins, return on equity and return on assets.

Summary

FibroGen beats ESSA Pharma on 7 of the 13 factors compared between the two stocks.

ESSA Pharma (NASDAQ:EPIX) and ALX Oncology (NASDAQ:ALXO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.

Insider and Institutional Ownership

63.4% of ESSA Pharma shares are owned by institutional investors. Comparatively, 73.5% of ALX Oncology shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares ESSA Pharma and ALX Oncology's revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for ESSA Pharma and ALX Oncology, as reported by MarketBeat.

ESSA Pharma presently has a consensus price target of $28.80, suggesting a potential upside of 6.82%. ALX Oncology has a consensus price target of $89.60, suggesting a potential upside of 9.94%. Given ALX Oncology's higher possible upside, analysts plainly believe ALX Oncology is more favorable than ESSA Pharma.

Profitability

This table compares ESSA Pharma and ALX Oncology's net margins, return on equity and return on assets.

Summary

ALX Oncology beats ESSA Pharma on 5 of the 5 factors compared between the two stocks.